Enhanced Prostate Cancer Gene Transfer and Therapy Using a Novel Serotype Chimera Cancer Terminator Virus (Ad.5/3-CTV)

Journal of Cellular Physiology

Volumn 229, Issue 1, 2014, Pages 34-43

  Azab, Belal M ^a,h   Dash, Rupesh ^a,g   Das, Swadesh K ^a   Bhutia, Sujit K ^a,f   Sarkar, Siddik ^a   Shen, Xue Ning ^a   Quinn, Bridget A ^a   Dent, Paul ^a,b   Dmitriev, Igor P ^c   Wang, Xiang Yang ^a,b   Curiel, David T ^c   Pellecchia, Maurizio ^d   Reed, John C ^d,e   Sarkar, Devanand ^a,b   Fisher, Paul B ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BURNHAM INSTITUTE   (United States)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f NATIONAL INSTITUTE OF TECHNOLOGY   (India)

^g INSTITUTE OF LIFE SCIENCES   (India)

^h UNIVERSITY OF JORDAN   (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CONDITIONALLY REPLICATING ADENOVIRUS; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; GLUCOSE REGULATED PROTEIN 78; GLUCOSE REGULATED PROTEIN 94; INTERLEUKIN 24; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ONCOLYTIC ADENOVIRUS; SABUTOCLAX; UNCLASSIFIED DRUG; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR LIKE MEMBRANE PROTEIN; ONCOLYTIC VIRUS; RECOMBINANT PROTEIN;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CELL VIABILITY; CHIMERA; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE CANCER; SEROTYPE; TRANSGENIC MOUSE; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS INFECTIVITY; ADENOVIRIDAE; ANIMAL; CELL SURVIVAL; DRUG SCREENING; GENE THERAPY; GENE TRANSFER; GENETICS; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PROSTATIC NEOPLASMS; SEROTYPING; TUMOR CELL LINE; ADENOVIRUS; PROSTATE TUMOR;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; COXSACKIE AND ADENOVIRUS RECEPTOR-LIKE MEMBRANE PROTEIN; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; MALE; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; SEROTYPING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891520616     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24408     Document Type: Article

References (68)

1. Anderson WF. 1998. Human gene therapy. Nature 392:25-30.
2. Azab B, Dash R, Das SK, Bhutia SK, Shen XN, Quinn BA, Sarkar S, Wang XY, Hedvat M, Dmitriev IP, Curiel DT, Grant S, Dent P, Reed JC, Pellecchia M, Sarkar D, Fisher PB. 2012. Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells. J Cell Physiol 227:2145-2153.
3. Bhang HE, Gabrielson KL, Laterra J, Fisher PB, Pomper MG. 2011. Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression. Nat Med 17:123-129.
4. Chada S, Mhashilkar AM, Ramesh R, Mumm JB, Sutton RB, Bocangel D, Zheng M, Grimm EA, Ekmekcioglu S. 2004. Bystander activity of Ad-mda7: Human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism. Mol Ther 10:1085-1095.
5. Cianfriglia F, Di Gregorio DA, Manieri A. 1999. Multiple primary tumours in patients with oral squamous cell carcinoma. Oral Oncol 35:157-163.
6. Cookson MM. 2001. Prostate cancer: Screening and early detection. Cancer Control 8:133-140.
7. Cunningham CC, Chada S, Merritt JA, Tong A, Senzer N, Zhang Y, Mhashilkar A, Parker K, Vukelja S, Richards D, Hood J, Coffee K, Nemunaitis J. 2005. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: A phase I study. Mol Ther 11:149-159.
8. Curiel DT, Fisher PB, editors. 2012. Applications of viruses for cancer therapy. Adv Cancer Res 115:1-334.
9. Damber JE, Aus G. 2008. Prostate cancer. Lancet 371:1710-1721.
10. Das SK, Sarkar S, Dash R, Dent P, Wang XY, Sarkar D, Fisher PB. 2012. Cancer terminator viruses and approaches for enhancing therapeutic outcomes. Adv Cancer Res 115:1-38.
11. Dash R, Bhutia SK, Azab B, Su ZZ, Quinn BA, Kegelmen TP, Das SK, Kim K, Lee SG, Park MA, Yacoub A, Rahmani M, Emdad L, Dmitriev IP, Wang XY, Sarkar D, Grant S, Dent P, Curiel DT, Fisher PB. 2010a. mda-7/IL-24: A unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine Growth Factor Rev 21:381-391.
12. Dash R, Dmitriev I, Su ZZ, Bhutia SK, Azab B, Vozhilla N, Yacoub A, Dent P, Curiel DT, Sarkar D, Fisher PB. 2010b. Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) improves therapeutic efficacy in low CAR prostate cancer cells. Cancer Gene Ther 17:447-456.
13. Dash R, Richards JE, Su ZZ, Bhutia SK, Azab B, Rahmani M, Dasmahapatra G, Yacoub A, Dent P, Dmitriev IP, Curiel DT, Grant S, Pellecchia M, Reed JC, Sarkar D, Fisher PB. 2010c. Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7/IL-24, an IL-10-related cytokine. Cancer Res 70:5034-5045.
14. Dash R, Azab B, Quinn BA, Shen X, Wang XY, Das SK, Rahmani M, Wei J, Hedvat M, Dent P, Dmitriev IP, Curiel DT, Grant S, Wu B, Stebbins JL, Pellecchia M, Reed JC, Sarkar D, Fisher PB. 2011a. Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc Natl Acad Sci USA 108:8785-8790.
15. Dash R, Azab B, Shen XN, Sokhi UK, Sarkar S, Su ZZ, Wang XY, Claudio PP, Dent P, Dmitriev IP, Curiel DT, Grant S, Sarkar D, Fisher PB. 2011b. Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic. Discov Med 11:46-56.
16. DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M, Hamper U, DeJong R, Detorie N, Rodriguez R, Haulk T, DeMarzo AM, Piantadosi S, Yu DC, Chen Y, Henderson DR, Carducci MA, Nelson WG, Simons JW. 2001. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 61:7464-7472.
17. Di Lorenzo G, De Placido S. 2006. Hormone refractory prostate cancer (HRPC): Present and future approaches of therapy. Int J Immunopathol Pharmacol 19:11-34.
18. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV, Sawyers CL. 2003. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4:223-238.
19. Eulitt PJ, Park MA, Hossein H, Cruikshanks N, Yang C, Dmitriev IP, Yacoub A, Curiel DT, Fisher PB, Dent P. 2011. Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery. Cancer Biol Ther 10:1290-1305.
20. Fisher PB. 2005. Is mda-7/IL-24 a "magic bullet" for cancer? Cancer Res 65:10128-10138.
21. Fisher PB, Gopalkrishnan RV, Chada S, Ramesh R, Grimm EA, Rosenfeld MR, Curiel DT, Dent P. 2003. mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: From the laboratory into the clinic. Cancer Biol Ther 2(Suppl. 1):S23-S37.
22. Fisher PB, Sarkar D, Lebedeva IV, Emdad L, Gupta P, Sauane M, Su ZZ, Grant S, Dent P, Curiel DT, Senzer N, Nemunaitis J. 2007. Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): Novel gene therapeutic for metastatic melanoma. Toxicol Appl Pharmacol 224:300-307.
23. Fukuhara H, Homma Y, Todo T. 2010. Oncolytic virus therapy for prostate cancer. Int J Urol 17:20-30.
24. Gopalkrishnan RV, Kang DC, Fisher PB. 2001. Molecular markers and determinants of prostate cancer metastasis. J Cell Physiol 189:245-256.
25. Greco A, Di Benedetto A, Howard CM, Kelly S, Nande R, Dementieva Y, Miranda M, Brunetti A, Salvatore M, Claudio L, Sarkar D, Dent P, Curiel DT, Fisher PB, Claudio PP. 2010. Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach. Mol Ther 18:295-306.
26. Hamed HA, Yacoub A, Park MA, Eulitt PJ, Dash R, Sarkar D, Dmitriev IP, Lesniak MS, Shah K, Grant S, Curiel DT, Fisher PB, Dent P. 2010. Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Mol Ther 18:1130-1142.
27. Howard CM, Forsberg F, Minimo C, Liu JB, Merton DA, Claudio PP. 2006. Ultrasound guided site specific gene delivery system using adenoviral vectors and commercial ultrasound contrast agents. J Cell Physiol 209:413-421.
28. Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB. 1995. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 11:2477-2486.
29. Jiang H, Su ZZ, Lin JJ, Goldstein NI, Young CS, Fisher PB. 1996. The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc Natl Acad Sci USA 93:9160-9165.
30. Koizumi N, Yamaguchi T, Kawabata K, Sakurai F, Sasaki T, Watanabe Y, Hayakawa T, Mizuguchi H. 2007. Fiber-modified adenovirus vectors decrease liver toxicity through reduced IL-6 production. J Immunol 178:1767-1773.
31. Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, Nokisalmi P, Raki M, Rajecki M, Guse K, Ranki T, Oksanen M, Holm SL, Haavisto E, Karioja-Kallio A, Laasonen L, Partanen K, Ugolini M, Helminen A, Karli E, Hannuksela P, Pesonen S, Joensuu T, Kanerva A, Hemminki A. 2010. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 18:1874-1884.
32. Lebedeva IV, Sarkar D, Su ZZ, Kitada S, Dent P, Stein CA, Reed JC, Fisher PB. 2003. Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene 22:8758-8773.
33. Lebedeva IV, Emdad L, Su ZZ, Gupta P, Sauane M, Sarkar D, Staudt MR, Liu SJ, Taher MM, Xiao R, Barral P, Lee SG, Wang D, Vozhilla N, Park ES, Chatman L, Boukerche H, Ramesh R, Inoue S, Chada S, Li R, De Pass AL, Mahasreshti PJ, Dmitriev IP, Curiel DT, Yacoub A, Grant S, Dent P, Senzer N, Nemunaitis JJ, Fisher PB. 2007a. mda-7/IL-24, novel anticancer cytokine: Focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (review). Int J Oncol 31:985-1007.
34. Lebedeva IV, Su ZZ, Emdad L, Kolomeyer A, Sarkar D, Kitada S, Waxman S, Reed JC, Fisher PB. 2007b. Targeting inhibition of K-ras enhances Ad.mda-7-induced growth suppression and apoptosis in mutant K-ras colorectal cancer cells. Oncogene 26:733-744.
35. Lebedeva IV, Washington I, Sarkar D, Clark JA, Fine RL, Dent P, Curiel DT, Turro NJ, Fisher PB. 2007c. Strategy for reversing resistance to a single anticancer agent in human prostate and pancreatic carcinomas. Proc Natl Acad Sci USA 104:3484-3489.
36. Lu QL, Liang HD, Partridge T, Blomley MJ. 2003. Microbubble ultrasound improves the efficiency of gene transduction in skeletal muscle in vivo with reduced tissue damage. Gene Ther 10:396-405.
37. Muruve DA. 2004. The innate immune response to adenovirus vectors. Hum Gene Ther 15:1157-1166.
38. Park MA, Hamed HA, Mitchell C, Cruickshanks N, Dash R, Allegood J, Dmitriev IP, Tye G, Ogretmen B, Spiegel S, Yacoub A, Grant S, Curiel DT, Fisher PB, Dent P. 2011. A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels. Mol Pharmacol 79:368-380.
39. Raki M, Sarkioja M, Escutenaire S, Kangasniemi L, Haavisto E, Kanerva A, Cerullo V, Joensuu T, Oksanen M, Pesonen S, Hemminki A. 2011. Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients. J Gene Med 13:253-261.
40. Sarkar D, Su ZZ, Lebedeva IV, Sauane M, Gopalkrishnan RV, Dent P, Fisher PB. 2002a. mda-7 (IL-24): Signaling and functional roles. Biotechniques Suppl 33:30-39.
41. Sarkar D, Su ZZ, Lebedeva IV, Sauane M, Gopalkrishnan RV, Valerie K, Dent P, Fisher PB. 2002b. mda-7 (IL-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. Proc Natl Acad Sci USA 99:10054-10059.
42. Sarkar D, Su ZZ, Vozhilla N, Park ES, Gupta P, Fisher PB. 2005a. Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc Natl Acad Sci USA 102:14034-14039.
43. Sarkar D, Su ZZ, Vozhilla N, Park ES, Randolph A, Valerie K, Fisher PB. 2005b. Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice. Cancer Res 65:9056-9063.
44. Sarkar D, Su ZZ, Fisher PB. 2006. Unique conditionally replication competent bipartite adenoviruses-cancer terminator viruses (CTV): Efficacious reagents for cancer gene therapy. Cell Cycle 5:1531-1536.
45. Sarkar D, Lebedeva IV, Gupta P, Emdad L, Sauane M, Dent P, Curiel DT, Fisher PB. 2007a. Melanoma differentiation associated gene-7 (mda-7)/IL-24: A 'magic bullet' for cancer therapy? Expert Opin Biol Ther 7:577-586.
46. Sarkar D, Lebedeva IV, Su ZZ, Park ES, Chatman L, Vozhilla N, Dent P, Curiel DT, Fisher PB. 2007b. Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Res 67:5434-5442.
47. Sarkar D, Su ZZ, Park ES, Vozhilla N, Dent P, Curiel DT, Fisher PB. 2008. A cancer terminator virus eradicates both primary and distant human melanomas. Cancer Gene Ther 15:293-302.
48. Sauane M, Gopalkrishnan RV, Sarkar D, Su ZZ, Lebedeva IV, Dent P, Pestka S, Fisher PB. 2003. MDA-7/IL-24: Novel cancer growth suppressing and apoptosis inducing cytokine. Cytokine Growth Factor Rev 14:35-51.
49. Sauane M, Su ZZ, Gupta P, Lebedeva IV, Dent P, Sarkar D, Fisher PB. 2008. Autocrine regulation of mda-7/IL-24 mediates cancer-specific apoptosis. Proc Natl Acad Sci USA 105:9763-9768.
50. Schenk E, Essand M, Bangma CH, Consortium GF, Barber C, Behr JP, Briggs S, Carlisle R, Cheng WS, Danielsson A, Dautzenberg IJ, Dzojic H, Erbacher P, Fisher K, Frazier A, Georgopoulos LJ, Hoeben R, Kochanek S, Koppers-Lalic D, Kraaij R, Kreppel F, Lindholm L, Magnusson M, Maitland N, Neuberg P, Nilsson B, Ogris M, Remy JS, Scaife M, Schooten E, Seymour L, Totterman T, Uil TG, Ulbrich K, Veldhoven-Zweistra JL, de Vrij J, van Weerden W, Wagner E, Willemsen R. 2010. Clinical adenoviral gene therapy for prostate cancer. Hum Gene Ther 21:807-813.
51. Siegel R, Naishadham D, Jemal A. 2012. Cancer statistics, 2012. CA Cancer J Clin 62:10-29.
52. Sirena D, Lilienfeld B, Eisenhut M, Kalin S, Boucke K, Beerli RR, Vogt L, Ruedl C, Bachmann MF, Greber UF, Hemmi S. 2004. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol 78:4454-4462.
53. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, Wilding G. 2006. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 14:107-117.
54. Sternberg CN. 2002. Highlights of contemporary issues in the medical management of prostate cancer. Crit Rev Oncol Hematol 43:105-121.
55. Su ZZ, Shi Y, Fisher PB. 1997. Subtraction hybridization identifies a transformation progression-associated gene PEG-3 with sequence homology to a growth arrest and DNA damage-inducible gene. Proc Natl Acad Sci USA 94:9125-9130.
56. Su ZZ, Goldstein NI, Jiang H, Wang MN, Duigou GJ, Young CS, Fisher PB. 1999. PEG-3, a nontransforming cancer progression gene, is a positive regulator of cancer aggressiveness and angiogenesis. Proc Natl Acad Sci USA 96:15115-15120.
57. Su Z, Shi Y, Fisher PB. 2000. Cooperation between AP1 and PEA3 sites within the progression elevated gene-3 (PEG-3) promoter regulate basal and differential expression of PEG-3 during progression of the oncogenic phenotype in transformed rat embryo cells. Oncogene 19:3411-3421.
58. Su Z, Lebedeva IV, Gopalkrishnan RV, Goldstein NI, Stein CA, Reed JC, Dent P, Fisher PB. 2001a. A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. Proc Natl Acad Sci USA 98:10332-10337.
59. Su Z, Shi Y, Friedman R, Qiao L, McKinstry R, Hinman D, Dent P, Fisher PB. 2001b. PEA3 sites within the progression elevated gene-3 (PEG-3) promoter and mitogen-activated protein kinase contribute to differential PEG-3 expression in Ha-ras and v-raf oncogene transformed rat embryo cells. Nucleic Acids Res 29:1661-1671.
60. Su ZZ, Gopalkrishnan RV, Narayan G, Dent P, Fisher PB. 2002. Progression elevated gene-3, PEG-3, induces genomic instability in rodent and human tumor cells. J Cell Physiol 192:34-44.
61. Su Z, Emdad L, Sauane M, Lebedeva IV, Sarkar D, Gupta P, James CD, Randolph A, Valerie K, Walter MR, Dent P, Fisher PB. 2005a. Unique aspects of mda-7/IL-24 antitumor bystander activity: Establishing a role for secretion of MDA-7/IL-24 protein by normal cells. Oncogene 24:7552-7566.
62. Su ZZ, Sarkar D, Emdad L, Duigou GJ, Young CS, Ware J, Randolph A, Valerie K, Fisher PB. 2005b. Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter. Proc Natl Acad Sci USA 102:1059-1064.
63. Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N, Netto G, Rich D, Mhashilkar A, Parker K, Coffee K, Ramesh R, Ekmekcioglu S, Grimm EA, van Wart Hood J, Merritt J, Chada S. 2005. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): Biologic outcome in advanced cancer patients. Mol Ther 11:160-172.
64. Ulasov IV, Rivera AA, Han Y, Curiel DT, Zhu ZB, Lesniak MS. 2007. Targeting adenovirus to CD80 and CD86 receptors increases gene transfer efficiency to malignant glioma cells. J Neurosurg 107:617-627.
65. Wang H, Li Z, Yumul R, Lara S, Hemminki A, Fender P, Lieber A. 2011. Multimerization of adenovirus serotype 3 fiber knob domains is required for efficient binding of virus to desmoglein 2 and subsequent opening of epithelial junctions. J Virol 85:6390-6402.
66. Wei J, Kitada S, Rega MF, Stebbins JL, Zhai D, Cellitti J, Yuan H, Emdadi A, Dahl R, Zhang Z, Yang L, Reed JC, Pellecchia M. 2009. Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem 52:4511-4523.
67. Wei J, Stebbins JL, Kitada S, Dash R, Placzek W, Rega MF, Wu B, Cellitti J, Zhai D, Yang L, Dahl R, Fisher PB, Reed JC, Pellecchia M. 2010. BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem 53:4166-4176.
68. Wolk K, Kunz S, Asadullah K, Sabat R. 2002. Cutting edge: Immune cells as sources and targets of the IL-10 family members? J Immunol 168:5397-5402.